Timing of Off-Label Dosing of Direct Oral Anticoagulants in Three Large Health Systems

Abstract

Background While direct oral anticoagulants (DOACs) may be viewed as simpler to manage then warfarin, they present their own unique management challenges resulting in frequent off-label dosing. It is unknown to what extent off-label dosing occurs when a patient is started on a DOAC versus later in their treatment.

Objectives We aimed to better characterize when off-label DOAC dosing is occurring and to evaluate the effectiveness of prescribing oversight using a registry-based intervention.

Methods We evaluated data from the Michigan Anticoagulation Quality Improvement Initiative (MAQI²) registry, a retrospective quality-improvement process using data abstractors, from 2018 to 2022 on the number of “alerts” that are generated in response to dosing deviating from the U.S. Food and Drug Administration instructions for atrial fibrillation (AF) and venous thromboembolism (VTE).

Results Among a sample of 789 to 1,022 annual AF patients and 381 to 484 annual VTE patients prescribed a DOAC in the MAQI² registry, off-label dosing was relatively common. Over the 5-year period (2018–2022), there were 569 alerts for AF patients and 162 alerts for VTE patients. Alerts occurred more frequently during follow-up than at the time of initial prescribing in AF patients (78.2 vs. 21.8%), but more commonly at initial prescribing in VTE patients (59.9 vs. 40.1%). After initial review by quality-improvement abstractors, 19.3% of AF alerts and 14.8% of VTE alerts resulted in contact to the prescriber. When the prescriber was contacted, it led to an intervention about 75% of the time for both populations. The most common intervention was a change in DOAC dosing.

Conclusion This study demonstrates the benefit of DOAC prescribing oversight using a registry-based intervention to monitor for off-label dosing for the entirety of the time period a patient is prescribed DOAC, particularly for patients with AF, as off-label prescribing occurs frequently during the follow-up period.

Keywords

DOACs - off-label - registry

• References

• 1 January CT, Wann LS, Calkins H. et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74 (01) 104-132
• 2 Stevens SM, Woller SC, Baumann Kreuziger L. et al. Executive summary. Chest 2021; 160 (06) 2247-2259
• 3 Barnes GD, Sippola E, Dorsch M. et al. Applying population health approaches to improve safe anticoagulant use in the outpatient setting: the DOAC Dashboard multi-cohort implementation evaluation study protocol. Implement Sci 2020; 15 (01) 83
• 4 Barra ME, Fanikos J, Connors JM, Sylvester KW, Piazza G, Goldhaber SZ. Evaluation of dose-reduced direct oral anticoagulant therapy. Am J Med 2016; 129 (11) 1198-1204
• 5 Steinberg BA, Shrader P, Thomas L. et al; ORBIT-AF Investigators and Patients. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry. J Am Coll Cardiol 2016; 68 (24) 2597-2604
• 6 Dawson T, DeCamillo D, Kong X. et al. Correcting inappropriate prescribing of direct oral anticoagulants: a population health approach. J Am Heart Assoc 2020; 9 (22) e016949
• 7 Basaran O, Filiz Basaran N, Cekic EG. et al. PRescriptiOn PattERns of oral anticoagulants in nonvalvular atrial fibrillation (PROPER study). Clin Appl Thromb Hemost 2017; 23 (04) 384-391
• 8 Trujillo-Santos J, Di Micco P, Dentali F. et al; RIETE Investigators. Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens. Thromb Haemost 2017; 117 (02) 382-389
• 9 Andreu-Cayuelas JM, Pastor-Pérez FJ, Puche CM. et al. Impact of variations in kidney function on nonvitamin K oral anticoagulant dosing in patients with atrial fibrillation and recent acute heart failure. Rev Esp Cardiol (Engl Ed) 2016; 69 (02) 134-140
• 10 Becattini C, Giustozzi M, Ranalli MG. et al. Variation of renal function over time is associated with major bleeding in patients treated with direct oral anticoagulants for atrial fibrillation. J Thromb Haemost 2018; 16 (05) 833-841
• 11 Allen AL, Lucas J, Parra D. et al. Shifting the paradigm: a population health approach to the management of direct oral anticoagulants. J Am Heart Assoc 2021; 10 (24) e022758
• 12 Dorsch MP, Chen CS, Allen AL. et al. Nationwide implementation of a population management dashboard for monitoring direct oral anticoagulants: insights from the veterans affairs health system. Circ Cardiovasc Qual Outcomes 2023; 16 (02) e009256
• 13 Burnett AE, Barnes GD. A call to action for anticoagulation stewardship. Res Pract Thromb Haemost 2022; 6 (05) e12757
• 14 Koolian M, Wiseman D, Mantzanis H, Kampouris N, Kerzner RS, Kahn SR. Anticoagulation stewardship: descriptive analysis of a novel approach to appropriate anticoagulant prescription. Res Pract Thromb Haemost 2022; 6 (06) e12758
• 15 Miele C, Taylor M, Shah A. Assessment of direct oral anticoagulant prescribing and monitoring pre- and post-implementation of a pharmacy protocol at a community teaching hospital. Hosp Pharm 2017; 52 (03) 207-213
• 16 Willeford A, Leiman V, Noel ZR. Impact of a pharmacist-to-dose direct oral anticoagulant protocol on medication errors at an academic medical center. JACCP J Am Coll Clin Pharm 2021; 4 (11) 1392-1400
• 17 Kapoor A, Patel P, Mbusa D. et al. Multicomponent pharmacist intervention did not reduce clinically important medication errors for ambulatory patients initiating direct oral anticoagulants. J Gen Intern Med 2023; 38 (16) 3526-3534
• 18 Derington CG, Goodrich GK, Xu S. et al. Association of direct oral anticoagulation management strategies with clinical outcomes for adults with atrial fibrillation. JAMA Netw Open 2023; 6 (07) e2321971
• 19 Schaefer JK, Errickson J, Gu X. et al. Assessment of an intervention to reduce aspirin prescribing for patients receiving warfarin for anticoagulation. JAMA Netw Open 2022; 5 (09) e2231973